VOLUME 21 - NUMBER 1 / January - March (Original articles / Artículos originales)
Gabriela A. Mimiaga-López, Servicio de Algología, Instituto Nacional de Cancerología, Ciudad de México, México
Ma. del Rocío Guillén-Núñez, Servicio de Algología, Instituto Nacional de Cancerología, Ciudad de México, México
José A. Rodríguez-Martínez, Servicio de Neuroimagen, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México
Ale I. González-Cázares, Servicio de Algología, Instituto Nacional de Cancerología, Ciudad de México, México
Ángel M. Juárez-Lemus, Servicio de Algología, Instituto Nacional de Cancerología, Ciudad de México, México
Objective: To determine the effectiveness of Tapentadol in cancer patients with neuropathic pain. Material and methods: A descriptive, longitudinal, observational and prospective study was carried out including patients with cancer diagnosis and neuropathic pain treated at the pain clinic between January 1, 2014 and December 31, 2019. Results: 63 patients with a mean age of 59.07 ± 11.06 years were included, of which 76.2% (n = 48) were female. In the EVERA (verbal analog scale) and DN4 (neuropathic pain in 4 questions) scales, a significant difference was observed after treatment and when Tapentadol was initially used, a lower proportion of adverse effects was observed. Conclusions: Tapentadol proved to be an equally effective tool as other treatments, both as an initial or rotation drug, and when used as first line, it had better tolerability.
Keywords: Tapentadol. Neuropathic pain. Opioids. Oncological pain.
